GAO Report on Clinical Research Inspections Encourages FDA to Care for its Clinical Inspection Program
FDA Law Blog: Biosimilars
MARCH 29, 2024
That report prompted a hearing on Capitol Hill in February of this year where HPM Counsel John Claud offered testimony. According to GAO, FDA is facing challenges with clinical research inspections to ensure that the sites that oversee the research that lead to drug approvals meet the necessary standards.
Let's personalize your content